microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches
Parkinson’s disease (PD) is the most prevalent central nervous system (CNS) movement disorder and the second most common neurodegenerative disease overall. PD is characterized by the progressive loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) within the midbrain,...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/18/12/2698 |
id |
doaj-87491235af9f49ee8d44aa8b0196fa2b |
---|---|
record_format |
Article |
spelling |
doaj-87491235af9f49ee8d44aa8b0196fa2b2020-11-25T01:42:02ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-12-011812269810.3390/ijms18122698ijms18122698microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic ApproachesLoredana Leggio0Silvia Vivarelli1Francesca L’Episcopo2Cataldo Tirolo3Salvo Caniglia4Nunzio Testa5Bianca Marchetti6Nunzio Iraci7Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Torre Biologica, Via S. Sofia 97, 95125 Catania, ItalyDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Torre Biologica, Via S. Sofia 97, 95125 Catania, ItalyNeuropharmacology Section, OASI Institute for Research and Care on Mental Retardation and Brain Aging (IRCCS), 94018 Troina, ItalyNeuropharmacology Section, OASI Institute for Research and Care on Mental Retardation and Brain Aging (IRCCS), 94018 Troina, ItalyNeuropharmacology Section, OASI Institute for Research and Care on Mental Retardation and Brain Aging (IRCCS), 94018 Troina, ItalyNeuropharmacology Section, OASI Institute for Research and Care on Mental Retardation and Brain Aging (IRCCS), 94018 Troina, ItalyDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Torre Biologica, Via S. Sofia 97, 95125 Catania, ItalyDepartment of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Torre Biologica, Via S. Sofia 97, 95125 Catania, ItalyParkinson’s disease (PD) is the most prevalent central nervous system (CNS) movement disorder and the second most common neurodegenerative disease overall. PD is characterized by the progressive loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) within the midbrain, accumulation of alpha-synuclein (α-SYN) in Lewy bodies and neurites and excessive neuroinflammation. The neurodegenerative processes typically begin decades before the appearance of clinical symptoms. Therefore, the diagnosis is achievable only when the majority of the relevant DAergic neurons have already died and for that reason available treatments are only palliative at best. The causes and mechanism(s) of this devastating disease are ill-defined but complex interactions between genetic susceptibility and environmental factors are considered major contributors to the etiology of PD. In addition to the role of classical gene mutations in PD, the importance of regulatory elements modulating gene expression has been increasingly recognized. One example is the critical role played by microRNAs (miRNAs) in the development and homeostasis of distinct populations of neurons within the CNS and, in particular, in the context of PD. Recent reports demonstrate how distinct miRNAs are involved in the regulation of PD genes, whereas profiling approaches are unveiling variations in the abundance of certain miRNAs possibly relevant either to the onset or to the progression of the disease. In this review, we provide an overview of the miRNAs recently found to be implicated in PD etiology, with particular focus on their potential relevance as PD biomarkers, as well as their possible use in PD targeted therapy.https://www.mdpi.com/1422-0067/18/12/2698parkinson’s diseasemicroRNAsbiomarkersexosomesneuroprotective therapies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Loredana Leggio Silvia Vivarelli Francesca L’Episcopo Cataldo Tirolo Salvo Caniglia Nunzio Testa Bianca Marchetti Nunzio Iraci |
spellingShingle |
Loredana Leggio Silvia Vivarelli Francesca L’Episcopo Cataldo Tirolo Salvo Caniglia Nunzio Testa Bianca Marchetti Nunzio Iraci microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches International Journal of Molecular Sciences parkinson’s disease microRNAs biomarkers exosomes neuroprotective therapies |
author_facet |
Loredana Leggio Silvia Vivarelli Francesca L’Episcopo Cataldo Tirolo Salvo Caniglia Nunzio Testa Bianca Marchetti Nunzio Iraci |
author_sort |
Loredana Leggio |
title |
microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches |
title_short |
microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches |
title_full |
microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches |
title_fullStr |
microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches |
title_full_unstemmed |
microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches |
title_sort |
micrornas in parkinson’s disease: from pathogenesis to novel diagnostic and therapeutic approaches |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2017-12-01 |
description |
Parkinson’s disease (PD) is the most prevalent central nervous system (CNS) movement disorder and the second most common neurodegenerative disease overall. PD is characterized by the progressive loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) within the midbrain, accumulation of alpha-synuclein (α-SYN) in Lewy bodies and neurites and excessive neuroinflammation. The neurodegenerative processes typically begin decades before the appearance of clinical symptoms. Therefore, the diagnosis is achievable only when the majority of the relevant DAergic neurons have already died and for that reason available treatments are only palliative at best. The causes and mechanism(s) of this devastating disease are ill-defined but complex interactions between genetic susceptibility and environmental factors are considered major contributors to the etiology of PD. In addition to the role of classical gene mutations in PD, the importance of regulatory elements modulating gene expression has been increasingly recognized. One example is the critical role played by microRNAs (miRNAs) in the development and homeostasis of distinct populations of neurons within the CNS and, in particular, in the context of PD. Recent reports demonstrate how distinct miRNAs are involved in the regulation of PD genes, whereas profiling approaches are unveiling variations in the abundance of certain miRNAs possibly relevant either to the onset or to the progression of the disease. In this review, we provide an overview of the miRNAs recently found to be implicated in PD etiology, with particular focus on their potential relevance as PD biomarkers, as well as their possible use in PD targeted therapy. |
topic |
parkinson’s disease microRNAs biomarkers exosomes neuroprotective therapies |
url |
https://www.mdpi.com/1422-0067/18/12/2698 |
work_keys_str_mv |
AT loredanaleggio micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches AT silviavivarelli micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches AT francescalepiscopo micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches AT cataldotirolo micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches AT salvocaniglia micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches AT nunziotesta micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches AT biancamarchetti micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches AT nunzioiraci micrornasinparkinsonsdiseasefrompathogenesistonoveldiagnosticandtherapeuticapproaches |
_version_ |
1725038244768251904 |